文献速递心外重症与机械循环支持

术前微轴流泵支持与耐久性左心室辅助装置植入后主动脉瓣反流及右心衰竭的关联

Aortic insufficiency and right heart failure in patients treated with durable left ventricular assist devices after preoperative support with microaxial flow devices.
PubMed 文献 · J Heart Lung Transplant · 2026-05-22

基于STS Intermacs数据库分析2020年11月至2024年12月植入全磁悬浮离心泵的成人患者,发现dLVAD术前使用mAFP与术后24个月≥中度主动脉瓣反流风险升高相关(PSM后21.4% vs 15.3%),且可能增加右心衰竭风险。

要点

  • dLVAD术前mAFP支持与24个月≥中度AI风险独立相关(Cox HR 1.79)。
  • PSM后mAFP组2年≥中度AI发生率21.4%,高于非tMCS组的15.3%。
  • mAFP与RHF风险升高相关(HR 1.34),PSM后呈趋势(HR 1.20)。

核心结论

  • 当代dLVAD植入前使用mAFP与术后新发中度或更严重主动脉瓣反流相关,并可能增加右心衰竭风险。

研究设计与样本

  • 回顾性队列研究,查询STS Intermacs数据库中2020年11月至2024年12月全磁悬浮离心泵成人植入患者。
  • AI分析纳入5,942例,排除术前≥中度AI或同期主动脉瓣修复者;RHF分析纳入6,079例,排除同期RVAD者。
  • 采用Cox多变量分析和倾向性评分匹配评估mAFP对术后AI和RHF的影响。

主要发现

  • AI分析中,无tMCS 1,936例(32.6%),IABP 1,979例(33.3%),mAFP 1,627例(27.4%),VA-ECMO 400例(6.7%)。
  • 校正其他危险因素后,mAFP与24个月无≥中度AI生存率降低相关(Cox HR 1.79 [1.43-2.24])。
  • PSM后mAFP组2年≥中度AI发生率21.4%,非tMCS组15.3%(HR 1.75 [1.29-2.38])。
  • RHF分析中24个月内1,220例(20.1%)发生RHF;mAFP组RHF风险升高(HR 1.33 [1.15-1.54]),校正后HR 1.34 [1.16-1.55]。
  • PSM后mAFP组RHF风险呈趋势(HR 1.20 [0.97-1.49])。

临床怎么用

  • dLVAD术前使用mAFP的患者应加强术后主动脉瓣反流和右心功能监测。
  • 考虑mAFP可能掩盖临床显著AI,dLVAD植入时需仔细评估主动脉瓣状态。

局限性

  • 原文未明确报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Temporary mechanical circulatory support (tMCS) with microaxial flow pumps (mAFP) reverses the shock state and improves hemodynamics prior to durable left ventricular assist device (dLVAD) implant. Aortic insufficiency (AI) and right heart failure (RHF) are recognized sourced of late morbidity and mortality during dLVAD support. We examined the impact of tMCS with mAFP on AI and RHF progression given their transaortic deployment and unique interaction with the aortic valve and right ventricle. METHODS: The Society of Thoracic Surgeons Intermacs Database was queried for all fully magnetically levitated centrifugal pump adult implants between 11-2020 and 12-2024. Patients with ≥ moderate preoperative AI or with concomitant aortic valve repair at dLVAD implant were excluded from the AI analysis and patients with concomitant RVADs were excluded from the RHF analysis. The impact of mAFP use prior to dLVAD implant on the development of post-implant AI and RHF was explored through Cox multivariable analysis and propensity score (PS) matching. Hazard ratio with 95% confidence interval (HR [95% CI]) is shown. RESULTS: Among 5,942 patients included in the AI analysis, there were 1,936 (32.6%) with no tMCS, 1,979 (33.3%) with intra-aortic balloon pump, 1,627 (27.4%) with mAFP, and 400 (6.7%) with veno-arterial extracorporeal membrane oxygenation prior to dLVAD. After adjustment for other risk factors, mAFP support pre-dLVAD was associated with lower freedom from ≥ moderate AI at 24 months (Cox HR 1.79 [1.43-2.24]). After PSM, mAFP patients were more likely to develop ≥ moderate AI at 2 years compared to non-tMCS patients (21.4% vs 15.3%; HR 1.75 [CI 1.29-2.38]). 6,079 patients were included in the RHF analysis, of which 1,220 (20.1%) developed RHF within 24 months of dLVAD implant. Patients supported with mAFPs prior to dLVAD had an increased risk of developing RHF after dLVAD (HR = 1.33 [1.15-1.54]). After adjustment for other risk factors for RHF, mAFP support pre-dLVAD was associated with greater likelihood of RHF at 24 months (HR 1.34 [1.16-1.55]). After PSM, there was a trend for development of RHF in dLVAD patients supported with preoperative mAFP (HR 1.20 [0.97-1.49]). CONCLUSION: Microaxial flow pump support prior to contemporary dLVAD implantation is associated with the development of moderate or worse de novo AI and may confer increased risk for RHF. Potential mechanisms, including damage to the valve apparatus and masking of clinically significant AI at the time of dLVAD, warrant further exploration.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Grinstein J, Cowger J, Elad B, et al. Aortic insufficiency and right heart failure in patients treated with durable left ventricular assist devices after preoperative support with microaxial flow devices. J Heart Lung Transplant. 2026. PMID: 42176716. doi:10.1016/j.healun.2026.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。